Jay Rothstein, Ph.D., has more than 30 years of experience as a translational immunobiologist leading discovery, PK/PD, toxicological assessment, and proof-of-concept models for immune-modulatory drugs. Most recently, he was Chief Scientific Officer at ImmuNext where he was instrumental in helping to establish five strategic research partnerships with leading pharmaceutical and biotech companies, including Eli Lilly, Sanofi, Roche, Janssen (Johnson & Johnson), and Curis. Previously, Dr. Rothstein was Director of Inflammation Research at Amgen where he championed a novel class of immunomodulatory drugs for the treatment of autoimmune disease. During his nine years at Amgen, he helped in cross-functional teams to evaluate and develop Amgen's early immune-oncology drug pipeline, which included novel bispecifics such as BiTEs, as well as novel drugs to target immunometabolism. Before Amgen, Dr. Rothstein was a Professor of Otolaryngology-HNS at the Kimmel Cancer Institute of Thomas Jefferson University for 13 years, where his laboratory was responsible for discovering an association between oncogenes and chronic inflammation leading to a better understanding of the tumor microenvironment. Dr. Rothstein holds a Ph.D. in Tumor Immunology from the University of Chicago and a B.S. in Microbiology/Molecular Biology from Pennsylvania State University.

Arthur Tzianabos, Ph.D., has over 30 years of experience in the biotechnology industry and academia leading teams in the discovery, development, clinical translation and commercialization of new treatments for immunology and rare diseases. Most recently, Dr. Tzianabos served as President and CEO of Homology Medicines and is currently Chair of the Board. During his previous tenure at Shire Pharmaceuticals plc, Dr. Tzianabos had an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire’s pipeline. Dr. Tzianabos is trained as an immunologist and was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos is a member of the Board of Directors for both Stoke Therapeutics and is on the Development Board for the University of New Hampshire’s College of Life Sciences and Agriculture. Previously, he was Chair of the Board for Akouos Therapeutics (acquired by Eli Lilly), on the Board of Oxford Biomedica Solutions, and a member of the Alliance for Regenerative Medicine’s Board of Directors and Executive Committee. He has published more than 80 scientific papers, reviews, book chapters and patents. Dr. Tzianabos holds a Ph.D. in Microbiology from the University of New Hampshire and a B.S. in Biology from Boston College.